title: Correlation Between E-cadherin Immunoexpression and Efficacy of First Line Platinum-Based Chemotherapy in Advanced High Grade Serous Ovarian Cancer.
abstract: To analyze correlation between immunoexpression of E-cadherin and efficacy of first line platinum-based chemotherapy in patients with advanced-stage high-grade serous ovarian carcinoma. The expression of E-cadherin was analyzed immunohistochemically in formalin-fixed, paraffin-embedded samples from 98 patients with advanced-stage high-grade serous ovarian cancer and related to clinical features (stage according to the International Federation of Gynecology and Obstetrics (FIGO) and residual tumors after initial cytoreductive surgery), response to platinum-based chemotherapy (according to Response Evaluation Criteria in Solid tumors (RECIST 1.1 criteria)), platinum sensitivity (according to platinum free interval (PFI) as platinum-refractory, platinum-resistant and platinum-sensitive) and patients progression free survival (PFS) and overall survival (OS). E-cadherin immunostaining was positive in 74 and negative in 24 serous ovarian carcinomas. E-cadherin immunoreactivity was not associated with FIGO stage, residual tumor after initial cytoreductive surgery and number of chemotherapy cycles. Positive E-cadherin expression predict significantly better response to first line platinum-based chemotherapy (p < 0.001) and platinum sensitivity (p < 0.001). Moreover, positive E-cadherin expression predict significantly longer PFS (p < 0.001) and OS (p < 0.001). The multivariate analysis for OS showed that positive E-cadherin expression is predictor to platinum sensitivity (p < 0.001) and longer OS (p = 0.01). Positive E-cadherin expression seems to be a predictor of better response to first line platinum-based chemotherapy, platinum sensitivity and favorable clinical outcome in patients with advanced-stage serous ovarian cancer. Negative E-cadherin expression was shown to be significant, independent predictor of poorer PFS and OS. E-cadherin as a marker has predictive and prognostic value.
authors.affiliation: Department of Oncology, Clinical Hospital Center Split, School of Medicine, University of Split, Spinčićeva 1, 21000, Split, Croatia, brapemi@gmail.com.
authors.forename: Branka Petrić
authors.initials: BP
authors.lastname: Miše
authors.forename: Vesna Dobrić
authors.initials: VD
authors.lastname: Telesmanić
authors.forename: Snježana
authors.initials: S
authors.lastname: Tomić
authors.forename: Dinka
authors.initials: D
authors.lastname: Šundov
authors.forename: Vesna
authors.initials: V
authors.lastname: Čapkun
authors.forename: Eduard
authors.initials: E
authors.lastname: Vrdoljak
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D014408:Biomarkers, Tumor; D015820:Cadherins / Q000378:metabolism*; D004358:Drug Therapy; D005260:Female; D015972:Gene Expression Regulation, Neoplastic / Q000502:physiology*; D006801:Humans; D008875:Middle Aged; D015999:Multivariate Analysis; D060787:Neoplasm Grading; D009367:Neoplasm Staging; D018297:Neoplasms, Cystic, Mucinous, and Serous / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D010984:Platinum / Q000627:therapeutic use*; D011379:Prognosis; D015996:Survival Rate; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D015820:Cadherins; D010984:Platinum
references.citation: Eur J Cancer. 2009 Jan;45(2):228-47
references.pmid: 19097774
references.citation: Crit Rev Oncol Hematol. 2007 Jul;63(1):12-31
references.pmid: 17336087
references.citation: Br J Cancer. 2008 Jan 29;98(2):489-95
references.pmid: 18026186
references.citation: Am J Surg Pathol. 2010 Mar;34(3):433-43
references.pmid: 20154587
references.citation: J Exp Clin Cancer Res. 2012 Feb 13;31:14
references.pmid: 22330607
references.citation: J Clin Oncol. 2003 Sep 1;21(17):3194-200
references.pmid: 12860964
references.citation: Clin Cancer Res. 2008 Mar 1;14(5):1291-5
references.pmid: 18316546
references.citation: Hum Pathol. 1997 Aug;28(8):922-8
references.pmid: 9269828
references.citation: J Cancer Res Clin Oncol. 2007 Feb;133(2):83-92
references.pmid: 16932944
references.citation: Hum Pathol. 2009 Sep;40(9):1213-23
references.pmid: 19552940
references.citation: Clin Biochem. 2013 Oct;46(15):1585-9
references.pmid: 23792261
references.citation: Pathol Int. 2006 Feb;56(2):62-70
references.pmid: 16445817
references.citation: J Clin Pathol. 2006 May;59(5):460-7
references.pmid: 16461565
references.citation: Cancer Res. 2006 Jan 15;66(2):944-50
references.pmid: 16424029
references.citation: Ann Oncol. 2004 Oct;15(10):1535-42
references.pmid: 15367415
references.citation: Asian Pac J Cancer Prev. 2012;13(5):2003-7
references.pmid: 22901162
references.citation: J Natl Cancer Inst. 2003 Sep 3;95(17):1320-9
references.pmid: 12953086
references.citation: Am J Surg Pathol. 2004 Apr;28(4):496-504
references.pmid: 15087669
references.citation: Am J Pathol. 2011 Jul;179(1):400-10
references.pmid: 21703419
references.citation: Cancer Cell Int. 2003 Oct 14;3(1):17
references.pmid: 14613514
references.citation: J Natl Cancer Inst. 2010 May 19;102(10):672-5
references.pmid: 20460631
references.citation: Mol Oncol. 2007 Dec;1(3):246-51
references.pmid: 19383299
references.citation: Anticancer Res. 2010 Oct;30(10):3903-10
references.pmid: 21036701
references.citation: BMC Cancer. 2006 Jul 31;6:201
references.pmid: 16879751
references.citation: Drugs. 2011 Jan 1;71(1):79-88
references.pmid: 21175241
references.citation: Am J Obstet Gynecol. 2008 Apr;198(4):351-6
references.pmid: 18395030
references.citation: BMC Cancer. 2011 Dec 07;11:509
references.pmid: 22152101
references.citation: Ann Surg Oncol. 2010 Jun;17(6):1642-8
references.pmid: 20165986
references.citation: Cold Spring Harb Perspect Biol. 2009 Dec;1(6):a003129
references.pmid: 20457567
references.citation: PLoS One. 2014 Jan 22;9(1):e86987
references.pmid: 24466305
references.citation: Oncology. 2004;66(2):150-9
references.pmid: 15138368
references.citation: Annu Rev Pathol. 2009;4:287-313
references.pmid: 18842102
references.citation: Nat Rev Cancer. 2009 Jun;9(6):415-28
references.pmid: 19461667
references.citation: Arch Gynecol Obstet. 2011 Aug;284(2):437-43
references.pmid: 20803206
references.citation: J Ovarian Res. 2014 Feb 06;7:16
references.pmid: 24499657
references.citation: Int J Gynaecol Obstet. 2014 Jan;124(1):1-5
references.pmid: 24219974
references.citation: Int J Gynecol Cancer. 2010 Dec;20(9):1490-7
references.pmid: 21119364
references.citation: Jpn J Clin Oncol. 2009 Sep;39(9):560-8
references.pmid: 19531543
references.citation: J Natl Cancer Inst. 2003 Mar 19;95(6):484-6
references.pmid: 12644542
references.citation: Biochim Biophys Acta. 2012 Aug;1826(1):23-31
references.pmid: 22440943
references.citation: Clin Cancer Res. 2011 Apr 15;17(8):2350-60
references.pmid: 21220476
references.citation: Arch Gynecol Obstet. 2013 Jun;287(6):1219-24
references.pmid: 23269354
references.citation: Hum Pathol. 2009 May;40(5):693-8
references.pmid: 19157508
references.citation: Female Patient (Parsippany). 2011;36(4):30-35
references.pmid: 21841893
references.citation: Oncol Lett. 2013 Apr;5(4):1295-1300
references.pmid: 23599782
references.citation: N Engl J Med. 1996 Jan 4;334(1):1-6
references.pmid: 7494563
references.citation: Breast Cancer Res Treat. 2008 Mar;108(2):233-40
references.pmid: 17468949
references.citation: Med Oncol. 2012 Mar;29(1):318-23
references.pmid: 21264536
references.citation: Tumour Biol. 2004 May-Jun;25(3):106-10
references.pmid: 15361706
references.citation: Curr Oncol. 2012 Feb;19(1):36-8
references.pmid: 22328840